TD Cowen analyst Marc Frahm has maintained their bullish stance on SRRK stock, giving a Buy rating yesterday.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marc Frahm has given his Buy rating due to a combination of factors including the promising developments in Scholar Rock Holding’s pipeline, particularly the advancements with apitegromab for the treatment of spinal muscular atrophy (SMA). The positive results from the Phase III SAPPHIRE trial, which demonstrated significant improvements in patients, suggest a strong potential for broad adoption of the therapy.
Furthermore, the regulatory progress with the FDA and EMA, including the acceptance of the Biologics License Application and Marketing Authorization Application, respectively, reinforces confidence in the potential approval and market launch. The expectation of a broad label for apitegromab, covering a wide range of SMA patients, along with limited payer resistance, supports the optimistic outlook and Buy recommendation for Scholar Rock Holding’s stock.